Stock AKESF AKESO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Akeso, Inc. Share Price OTC Markets

Equities

AKESF

KYG0146B1032

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 14:30:23 04/06/2024 BST 		5-day change 1st Jan Change
5.62 USD -1.40% Intraday chart for Akeso, Inc. +21.28% 0.00%
06-04 Akeso Expands Territory of License Agreement for Lung Cancer Drug MT
06-03 Summit Therapeutics Inc. Expands License Territories for Ivonescimab CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 2.67B 369M 28.93B Sales 2025 * 4.31B 595M 46.63B Capitalization 35.47B 4.9B 384B
Net income 2024 * -441M -60.92M -4.77B Net income 2025 * 233M 32.19M 2.52B EV / Sales 2024 * 13.9 x
Net Debt 2024 * 1.71B 237M 18.53B Net Debt 2025 * 420M 58.09M 4.55B EV / Sales 2025 * 8.33 x
P/E ratio 2024 *
-76.4 x
P/E ratio 2025 *
145 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 73.33%
More Fundamentals * Assessed data

Chart Akeso, Inc.

Dynamic Chart

Latest news about Akeso, Inc.

Akeso Expands Territory of License Agreement for Lung Cancer Drug MT
Summit Therapeutics Inc. Expands License Territories for Ivonescimab CI
Akeso's Phase 3 Trial for Non-Small Cell Lung Cancer Treatment Meets Primary Endpoint; Shares Rise 15% MT
Akeso, Inc. Announces Registration Phase III Clinical Trial, AK112-303 (HARMONi-2) of ivonescimab (AK112, PD-1/VEGF) CI
Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival CI
Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut MT
Akeso Lung Cancer Drug Gets NMPA's Marketing Approval; Stocks Crash 20% MT
Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection CI
Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator MT
National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer CI
Akeso to Raise Over HK$1 Billion Via Share Sale MT
Akeso Logs First-Ever Profit in 2023; Beats EPS Forecast MT
Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC CI
Akeso Books First-Ever Profit in 2023; Shares Fall 5% MT
More news

Analyst Recommendations on Akeso, Inc.

Nomura Adjusts Akeso’s Price Target to HK$52.80 From HK$48.84, Keeps at Buy MT
Nomura Adjusts Akeso's Price Target to HK$48.84 From HK$50.14, Keeps at Buy MT
Nomura Adjusts Akeso's Price Target to HK$50.14 From HK$46.04, Keeps at Buy MT
Nomura Adjusts Akeso's Price Target to HK$46.04 From HK$31.54, Keeps at Buy MT
Nomura Adjusts Akeso's Price Target to HK$31.54 From HK$35.81, Keeps at Buy MT
More recommendations

Press releases Akeso, Inc.

Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 AQ
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024 AQ
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference AQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023 AQ
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap PR
More press releases

Quotes and Performance

1 week+19.57%
Current month+0.58%
3 months-1.40%
More quotes

Highs and lows

1 week
4.30
Extreme 4.3
5.75
More quotes

Managers and Directors - Akeso, Inc.

Managers TitleAgeSince
Baiyong Li FOU
 Founder 56 18/03/12
Peng Zhang FOU
 Founder 48 18/03/12
Michelle Xia CEO
 Chief Executive Officer 57 18/03/12
Members of the board TitleAgeSince
Bo Tan BRD
 Director/Board Member 51 31/03/20
Zhongmin Wang FOU
 Founder 55 18/03/12
Yan Xu BRD
 Director/Board Member 61 31/03/20
More insiders

Quotes

Date Price Change
04/06/24 5.62 -1.40%
03/06/24 5.7 +2.01%
31/05/24 5.588 +1.59%
30/05/24 5.5 +27.91%

Delayed Quote OTC Markets, June 04, 2024 at 02:30 pm

More quotes

Company Profile

Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.
Sector
Biotechnology & Medical Research
Calendar
19/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Akeso, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
40.96 CNY
Average target price
54.76 CNY
Spread / Average Target
+33.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.73% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+13.04% 107B
BIONTECH SE Stock BioNTech SE
-5.80% 24.82B
ARGENX SE Stock argenx SE
+1.69% 22.48B
GENMAB A/S Stock Genmab A/S
-10.09% 18.32B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.52% 16.33B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.00% 15.31B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.18% 14.08B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+24.18% 11.74B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 9926 Stock
  4. AKESF Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW